The oncogenic receptor tyrosine kinases are key to lung cancer malignant transformation, as evidenced by the clinical successes of EGFR, MET, and EML4-ALK inhibition by small molecule therapeutics [7,8]. This evidence concerns the gene EML4 and lung carcinoma.